发明名称 ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS
摘要 Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
申请公布号 US2016030497(A1) 申请公布日期 2016.02.04
申请号 US201314646233 申请日期 2013.11.21
申请人 DUKE UNIVERSITY 发明人 GROMEIER Matthias;SAMPSON John H.;BIGNER Darell D.;DESJARDINS Annick;FRIEDMAN Henry S.
分类号 A61K35/768;A61K9/00;A61N5/10;A61K51/08;A61K45/06;C12N7/00;A61K41/00 主分类号 A61K35/768
代理机构 代理人
主权项 1. A method of treating a human harboring a solid tumor which expresses NECL5 (nectin-like protein 5), said method comprising the steps of: administering directly to the tumor in the human a chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in said poliovirus' 5′ untranslated region between said poliovirus' cloverleaf and said poliovirus' open reading frame.
地址 Durham NC US